Avidity
Nhin Lu has extensive experience in the biopharmaceutical industry, with a focus on research and scientific roles. They have worked at various companies throughout their career, starting in 2002 as an Intern/Research Associate at X-Ceptor Therapeutics Inc. From there, they worked at Exelixis as an Associate Research Scientist I, Lead Discovery from 2004 to 2010.
In 2010, Nhin joined both Takeda and Aragon Pharmaceuticals, Inc. as a Senior Research Associate, staying at both companies until 2013. They then had a brief consulting role at Seragon Pharmaceuticals before taking a gap year sabbatical in 2014. During their sabbatical, they worked on personal projects.
Afterwards, Nhin joined Metacrine, Inc. in 2015 as a Research Associate III, and subsequently held other roles at the company including Senior Research Associate and Senior Associate Scientist. They remained at Metacrine, Inc. until 2022.
Most recently, Nhin joined Avidity Biosciences, Inc. in 2022 as a Biomarkers Associate Scientist. Their work experience demonstrates their expertise and dedication to the field of biopharmaceutical research.
Nhin Lu has obtained a Bachelor of Science degree in Cell Biology from UC San Diego. The specific start and end years of their education at this institution are not provided.
Avidity
2 followers
Avidity Biosciences is pioneering a new class of precision medicines – antibody-siRNA conjugates (ASC™) – to deliver nucleic acid therapeutics against genetic drivers of disease. Our ASCs have drug-like properties similar to antibodies and antibody-drug conjugates. Importantly, their unique siRNA-based “payloads” permit selective targeting of disease-associated mRNAs against virtually any target of interest.